Oncologist

Oncologists work at the center of one of medicine's most emotionally and intellectually demanding fields. Their patients are frightened, often facing a disease that threatens their lives, and looking for honesty about odds alongside genuine hope where it exists. The best oncologists carry both.

The technical scope of the job has expanded dramatically over the past decade. Cancer treatment is no longer dominated by broad cytotoxic chemotherapy — today's oncologist must navigate genomic tumor profiling, biomarker-selected targeted therapies, checkpoint inhibitor immunotherapy protocols, antibody-drug conjugates, and a clinical trial landscape that changes faster than practice guidelines can keep pace with. A patient with metastatic non-small-cell lung cancer in 2026 may qualify for a first-line targeted agent based on EGFR, ALK, ROS1, KRAS, or MET alterations — or for a combination immunotherapy regimen based on PD-L1 expression — or for a clinical trial testing a novel combination. Sorting through those options is a knowledge-intensive task.

The multidisciplinary side of the role is equally significant. Tumor board conferences happen weekly at most cancer programs, and the medical oncologist's input shapes not just chemotherapy decisions but surgical timing, radiation sequencing, and the question of whether a patient's goals align with aggressive treatment. Oncologists who understand surgical and radiation oncology well enough to have those conversations as peers — rather than simply deferring or arguing past each other — deliver better coordinated care.

Beyond the clinical decisions, oncologists spend substantial time in patient communication. Breaking bad news, discussing prognosis, and navigating end-of-life goals-of-care conversations are not ancillary skills — they are central to the practice, and they require training and intentional development that medical school barely touches.

Education and training path:

• MD or DO degree from accredited medical school (4 years)
• Internal medicine residency (3 years) — required for hematology/oncology fellowship
• Hematology/Oncology fellowship via NRMP match (3 years for combined hem/onc; 2 years for oncology only at some programs)
• Optional subspecialty fellowship (breast oncology, GI oncology, neuro-oncology) for further specialization

Board certification:

• American Board of Internal Medicine (ABIM) certification in Internal Medicine (prerequisite)
• ABIM subspecialty certification in Medical Oncology or Hematology and Medical Oncology
• Maintenance of Certification (MOC) required every 10 years

Procedural skills:

• Bone marrow biopsy and aspiration (hematologist-oncologists)
• Lumbar puncture for CNS staging and intrathecal chemotherapy administration
• Central venous catheter placement (at some community practices without dedicated proceduralists)
• Thoracentesis and paracentesis for malignant effusions

Core clinical knowledge areas:

• Molecular oncology: oncogenes, tumor suppressor pathways, DNA repair mechanisms
• Pharmacology: mechanism, dosing, toxicity, and drug interactions for major chemotherapy and biologic agents
• Radiation oncology principles: fractionation, field design, toxicity syndromes — sufficient to collaborate effectively
• Palliative care and symptom management: opioid prescribing, antiemetic protocols, corticosteroid use

What differentiates effective oncologists in practice:

• Facility with ambiguity — oncology rarely offers a clearly correct answer
• Willingness to have direct conversations about prognosis and dying
• Intellectual curiosity that keeps pace with a rapidly evolving evidence base

Oncology is one of the highest-demand physician specialties in the U.S., and that demand is structural rather than cyclical. Cancer incidence increases with age, and the U.S. population is aging. The American Cancer Society estimates that cancer will be diagnosed in approximately two million Americans in 2026, and incidence is projected to grow. At the same time, the workforce pipeline — limited fellowship positions, long training timelines — cannot respond quickly to demand shifts.

The Association of American Medical Colleges has projected significant oncology physician shortages over the next decade, particularly in community and rural settings where access to subspecialty cancer care is already limited. Community oncologists — generalists managing a broad range of solid tumors — are in particularly short supply in markets outside major metro areas.

On the practice environment side, consolidation continues. Large health systems and private equity-backed oncology groups have been acquiring independent practices at a rapid pace. This has implications for income (often higher short-term under PE ownership, with different long-term incentives) and for practice culture. Academic oncology has remained relatively stable, with the research and teaching mission insulating it from the economics of private equity acquisition.

Treatment intensity is increasing, and with it the complexity of managing patients. Patients who would have had short survival with stage IV cancer in 2010 are now living years longer on effective targeted and immunotherapy regimens — which means more total patient-years of care, more complex toxicity management, and more difficult end-of-life conversations happening later in longer disease courses.

For physicians entering oncology, the career offers strong financial compensation, genuine intellectual challenge, and the kind of patient relationship depth that most specialties don't provide. The emotional sustainability demands are real and should be factored honestly into career decisions.

Dear Search Committee,

I'm applying for the Medical Oncologist position at [Cancer Center]. I'm completing my third year of hematology/oncology fellowship at [Program] and will be board-eligible in internal medicine and medical oncology upon finishing in June.

My fellowship has been deliberately broad — I've managed roughly equal volumes of solid tumor and hematologic malignancy cases. On the solid tumor side, I've had the most clinical depth in thoracic oncology, where our program treats a high volume of EGFR-mutated and ALK-rearranged lung cancers, and in GI oncology including MSI-high colorectal and HER2-positive gastric cases enrolled in immunotherapy trials. I've enrolled 14 patients in Phase I and II trials over the past two years and understand the protocol compliance and IRB reporting responsibilities that entails.

The aspect of fellowship that surprised me most was how much the quality of multidisciplinary communication matters. I've seen tumor board function well when all specialties are genuinely curious about each other's constraints, and I've seen it function poorly when people are presenting rather than consulting. I work hard at the former.

I'm drawn to [Cancer Center] specifically because of the community outreach infrastructure. A significant part of my patient volume has come from referring communities where access to subspecialty oncology is limited, and I've found that work meaningful in a way that academic referral centers don't always replicate.

I'd welcome the opportunity to discuss the position and your program's direction.

Sincerely, [Your Name]